BioNTech SE Sponsored ADR (NASDAQ:BNTX) Sees Significant Decline in Short Interest

BioNTech SE Sponsored ADR (NASDAQ:BNTX) saw a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 3,537,489 shares, a drop of 20.7% from the February 26th total of 4,462,537 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average daily volume of 2,504,103 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Trading of BioNTech

Institutional investors have recently bought and sold shares of the stock. Vontobel Holding Ltd. raised its stake in BioNTech by 17.9% during the third quarter. Vontobel Holding Ltd. now owns 72,096 shares of the company’s stock worth $7,110,000 after acquiring an additional 10,924 shares in the last quarter. Long Focus Capital Management LLC boosted its stake in shares of BioNTech by 91.3% in the 3rd quarter. Long Focus Capital Management LLC now owns 397,655 shares of the company’s stock valued at $39,217,000 after purchasing an additional 189,752 shares in the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of BioNTech by 36.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 205,004 shares of the company’s stock worth $20,217,000 after purchasing an additional 55,004 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of BioNTech by 97.0% in the 3rd quarter. Victory Capital Management Inc. now owns 413,685 shares of the company’s stock worth $37,531,000 after purchasing an additional 203,700 shares during the last quarter. Finally, Dodge & Cox acquired a new stake in shares of BioNTech during the 2nd quarter worth about $93,421,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Down 2.0%

Shares of BNTX opened at $85.68 on Friday. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $103.70 and a two-hundred day moving average price of $101.60. The stock has a market cap of $20.56 billion, a price-to-earnings ratio of -16.35 and a beta of 1.51. BioNTech has a 12 month low of $79.52 and a 12 month high of $124.00.

Wall Street Analyst Weigh In

BNTX has been the subject of several research analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Wednesday. Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Finally, UBS Group upgraded shares of BioNTech to a “hold” rating in a research note on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.73.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.